Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB)
XTLB Stock Predictions and Ratings
WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-7.70%
Analyst Rating:
NOT AVAILABLE
Analyst Forecast (1yr):
NOT AVAILABLE
XTLB Stock Analysis
XTLB
PE Ratio:
XTLB
PEG Ratio:
Not Available
XTLB
Forward EPS Growth (12 month):
0.00%
XTLB
PS Ratio:
11.9
XTLB
PSG Ratio:
Not Available
XTLB
Forward Revenue Growth (12 month):
0.00%
XTLB Articles
No data was found